Retatrutide
$150 AUD
For laboratory research use only. Not for human consumption. Must be handled by qualified researchers in accordance with applicable regulations.
Overview
Retatrutide (LY3437943) is an investigational acylated peptide that functions as a triple receptor agonist, simultaneously targeting the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). It is supplied in lyophilised form at 10mg.
Scientific Overview
Clinical and preclinical research has positioned Retatrutide among the most potent investigational agents for obesity and metabolic disease. Phase 2 clinical trials have reported substantial reductions in body weight in adults with obesity. Research has examined its effects on adipose tissue lipolysis, energy expenditure, hepatic lipid metabolism, and markers of cardiovascular risk, as well as NASH and type 2 diabetes models.
Mechanism of Action
Triple agonism at GLP-1R, GIPR, and GCGR produces complementary metabolic effects. GLP-1R activation suppresses appetite and slows gastric emptying; GIPR co-agonism enhances glucose-dependent insulin secretion and potentiates GLP-1 action; GCGR agonism increases hepatic glucose output and directly stimulates adipose lipolysis and thermogenesis. The combined activation results in greater energy expenditure and fat mobilisation than single or dual agonists in preclinical models.
Areas of Research
Third-Party Testing
Every batch of Retatrutide supplied by Pure Recovery Labs is independently analysed by a third-party laboratory prior to release. Purity is confirmed via HPLC and mass spectrometry to a minimum of 99%. A certificate of analysis is accessible via QR code on each product and through the Quality page.
Research Use Only
Retatrutide is supplied exclusively for in vitro and preclinical laboratory research. It is not intended for, and must not be used in, humans or animals. It is not a medicinal product, therapeutic agent, supplement, cosmetic, or food substance. All handling must comply with applicable institutional and regulatory requirements. Pure Recovery Labs makes no claims regarding therapeutic efficacy or safety in any biological system.